|
1
|
Metz DC and Jensen RT: Gastrointestinal
neuroendocrine tumors: pancreatic endocrine tumors.
Gastroenterology. 135:1469–1492. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
de Wilde RF, Edil BH, Hruban RH and Maitra
A: Well-differentiated pancreatic neuroendocrine tumors: from
genetics to therapy. Nat Rev Gastroenterol Hepatol. 9:199–208.
2012.PubMed/NCBI
|
|
3
|
Panzuto F, Nasoni S, Falconi M, et al:
Prognostic factors and survival in endocrine tumor patients:
comparison between gastrointestinal and pancreatic localization.
Endocr Relat Cancer. 12:1083–1092. 2005. View Article : Google Scholar
|
|
4
|
Yao JC, Hassan M, Phan A, et al: One
hundred years after ‘carcinoid’: epidemiology of and prognostic
factors for neuroendocrine tumors in 35,825 cases in the United
States. J Clin Oncol. 26:3063–3072. 2008.
|
|
5
|
Bloomston M, Muscarella P, Shah MH, et al:
Cytoreduction results in high perioperative mortality and decreased
survival in patients undergoing pancreatectomy for neuroendocrine
tumors of the pancreas. J Gastrointest Surg. 10:1361–1370. 2006.
View Article : Google Scholar
|
|
6
|
Kobayashi N, Hiraoka N, Yamagami W, et al:
FOXP3+ regulatory T cells affect the development and
progression of hepatocarcinogenesis. Clin Cancer Res. 13:902–911.
2007.
|
|
7
|
Galon J, Costes A, Sanchez-Cabo F, et al:
Type, density, and location of immune cells within human colorectal
tumors predict clinical outcome. Science. 313:1960–1964. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiao Y, Shi C, Edil BH, et al:
DAXX/ATRX, MEN1, and mTOR pathway genes are
frequently altered in pancreatic neuroendocrine tumors. Science.
331:1199–1203. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nave BT, Ouwens M, Withers DJ, Alessi DR
and Shepherd PR: Mammalian target of rapamycin is a direct target
for protein kinase B: identification of a convergence point for
opposing effects of insulin and amino-acid deficiency on protein
translation. Biochem J. 344:427–431. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wullschleger S, Loewith R and Hall MN: TOR
signaling in growth and metabolism. Cell. 124:471–484. 2006.
View Article : Google Scholar
|
|
11
|
Yao JC, Shah MH, Ito T, et al: Everolimus
for advanced pancreatic neuroendocrine tumors. N Engl J Med.
364:514–523. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Crippa S, Partelli S, Boninsegna L and
Falconi M: Implications of the new histological classification (WHO
2010) for pancreatic neuroendocrine neoplasms. Ann Oncol.
23:19282012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cho Y, Miyamoto M, Kato K, et al:
CD4+ and CD8+ T cells cooperate to improve
prognosis of patients with esophageal squamous cell carcinoma.
Cancer Res. 63:1555–1559. 2003.
|
|
14
|
de Wilde RF, Heaphy CM, Maitra A, et al:
Loss of ATRX or DAXX expression and concomitant acquisition of the
alternative lengthening of telomeres phenotype are late events in a
small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.
Mod Pathol. 25:1033–1039. 2012.
|
|
15
|
La Rosa S, Klersy C, Uccella S, et al:
Improved histologic and clinicopathologic criteria for prognostic
evaluation of pancreatic endocrine tumors. Hum Pathol. 40:30–40.
2009.PubMed/NCBI
|
|
16
|
Scarpa A, Mantovani W, Capelli P, et al:
Pancreatic endocrine tumors: improved TNM staging and
histopathological grading permit a clinically efficient prognostic
stratification of patients. Mod Pathol. 23:824–833. 2010.
View Article : Google Scholar
|
|
17
|
Katz SC, Donkor C, Glasgow K, et al: T
cell infiltrate and outcome following resection of
intermediate-grade primary neuroendocrine tumours and liver
metastases. HPB. 12:674–683. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Han X, Ji Y, Zhao J, Xu X and Lou W:
Expression of PTEN and mTOR in pancreatic neuroendocrine tumors.
Tumour Biol. 34:2871–2879. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ino Y, Yamazaki-Itoh R, Shimada K, et al:
Immune cell infiltration as an indicator of the immune
microenvironment of pancreatic cancer. Br J Cancer. 108:914–923.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tsuchikawa T, Hirano S, Tanaka E, et al:
Novel aspects of preoperative chemoradiation therapy improving
anti-tumor immunity in pancreatic cancer. Cancer Sci. 104:531–535.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Marinoni I, Kurrer AS, Vassella E, et al:
Loss of DAXX and ATRX are associated with chromosome instability
and reduced survival of patients with pancreatic neuroendocrine
tumors. Gastroenterology. 146:453–460.e5. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Inada S, Koto T, Futami K, Arima S and
Iwashita A: Evaluation of malignancy and the prognosis of
esophageal cancer based on an immunohistochemical study (p53,
E-cadherin, epidermal growth factor receptor). Surg Today.
29:493–503. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Garcia I, Vizoso F, Martin A, et al:
Clinical significance of the epidermal growth factor receptor and
HER2 receptor in resectable gastric cancer. Ann Surg Oncol.
10:234–241. 2003. View Article : Google Scholar : PubMed/NCBI
|
